TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6668225
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of ascorbate daily
Study: 30365922
Drug: Gabapentin (1200-3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1200-3000 mg/d)
Study: 14992000
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of sibutramine hydrochloride capsule
Study: 14992000
Drug: Reference sibutramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference sibutramine capsules
Study: 8742097
Drug: G‐CSF 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 5 mu g/kg
Study: 8742097
Drug: G‐CSF 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 8 mu g/kg
Study: 8742097
Drug: G‐CSF 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 10 mu g/kg
Study: 3893778
Drug: Fansimef (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine per tablet) - 1 tablet
Study: 3893778
Drug: Fansimef (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine per tablet) - 2 tablets
Study: 3893778
Drug: Fansimef (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine per tablet) - 3 tablets
Study: 3893778
Drug: Fansimef (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansimef (all doses)
Study: 3893778
Drug: Fansimef (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansimef (3 tablets)
Study: 30419096
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (individualized moderate-intensity resistance, balance, and walking exercises, 2 daily sessions)
Study: 18576903
Drug: Dicloxacillin 500
Normalized name: dicloxacillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicloxacillin 500 mg alone
Study: 18576903
Drug: Dicloxacillin 500
Normalized name: dicloxacillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicloxacillin 500 mg plus probenecid 1 g
Study: 18576903
Drug: Dicloxacillin 500
Normalized name: dicloxacillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicloxacillin 500 mg plus cyclosporine 5 mg/kg
Study: 15765455
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine
Study: 12455724
Drug: Antioxidant treatment
Normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant treatment with glutathione (1200 mg i.v. at the end of each dialysis session) and a vitamin E-bonded HD membrane (CL-E)
Study: 1936472
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (metformin + glibenclamide), n = 60
Study: 1936472
Drug: Metformin monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy, n = 28
Study: 1936472
Drug: Glibenclamide monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide monotherapy, n = 28
Study: 7252648
Drug: Nitrogen intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen intake at 494 to 655 mg/kg/day with constant low energy intake (mean = 53 kcal/kg/day)
Study: 7252648
Drug: Energy intake
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy intake greater than 70 kcal/kg/day with nitrogen infusion of 430 to 560 mg/kg/day (2.7 to 3.5 gm protein/kg/day)
Study: 28755104
Drug: Oral mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mirtazapine (30 mg)
Study: 21298294
Drug: Levobupivacaine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 5 mg combined with fentanyl 25 μg
Study: 21298294
Drug: Levobupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 7.5 mg combined with fentanyl 15 μg
Study: 21298294
Drug: Levobupivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 10 mg combined with fentanyl 10 μg
Study: 16137055
Drug: 5-day rabeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day rabeprazole-based triple therapy (rabeprazole 10 mg twice daily, clarithromycin 500 mg twice daily, furazolidone 100 mg twice daily)
Study: 16137055
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple standard therapy (rabeprazole 10 mg twice daily, clarithromycin 500 mg twice daily, furazolidone 100 mg twice daily)
Study: 16137055
Drug: 5-day rabeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day rabeprazole-based triple therapy
Study: 16137055
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple standard therapy
Study: 9401929
Drug: Flurbiprofen (Froben)
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen (Froben) 50 mg, 3 times per day for 30 days
Study: 8419023
Drug: t-PA (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: t-PA (0.8 mg/kg i.v.; maximum, 80 mg) plus conventional antianginal therapy
Study: 8419023
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus conventional antianginal therapy
Study: 31820599
Drug: Jingu three-needle
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jingu three-needle therapy combined with Xingnao Kaiqiao acupuncture
Study: 29505863
Drug: Topical fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluorouracil (5‐FU) 5%
Study: 27553623
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment (PBMT with 904-nm GaAs diode laser, 30 mW average power, 25 Hz pulse frequency, 3.6 J/cm2)
Study: 27553623
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment (PBMT)
Study: 24920270
Drug: Chlorella (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella (5 g/day)
Study: 20455694
Drug: L. fermentum
Normalized name: L. fermentum/L. gasseri/L. plantarum/vitamin C/cranberry 3.5 billion cell-30 mg-250 mg ORAL CAPSULE
DrugBank: Lactobacillus fermentum (DB16542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. fermentum CECT5716 (Group A)
Study: 20455694
Drug: L. salivarius
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. salivarius CECT5713 (Group B)
Study: 20455694
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (Group C)
Study: 19017589
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy plus cognitive behavior therapy
Study: 15458100
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) technology used in developed virtual environments (VE) for the treatment of eating disorders.
Study: 12135314
Drug: L-NMMA (nitric
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (nitric oxide synthase inhibitor)
Study: 7517409
Drug: Zatosetron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zatosetron (50 mg) in men
Study: 4947492
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily continuation chemotherapy with isoniazid plus PAS
Study: 4947492
Drug: Fully supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully supervised treatment with streptomycin and high dosage isoniazid, given twice weekly
Study: 4578361
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months sanatorium treatment
Study: 17257450
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) with therapeutic drug monitoring (TDM) of mycophenolic acid (MPA) trough levels
Study: 17257450
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) without therapeutic drug monitoring (TDM)
Study: 12771969
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g spread enriched with 1.6 g plant sterols as fatty acid esters
Study: 11025373
Drug: Postoperative hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative hormonal treatment
Study: 7943921
Drug: Intravenous induction
Normalized name: Intravenous induction agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous induction with sodium thiopental and muscle relaxants (succinylcholine chloride or alcuronium chloride)
Study: 7943921
Drug: Awake intubation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awake intubation under intravenous sedation with diazepam and topical anesthesia with 4% lidocaine
Study: 31994366
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide synthase inhibitors
Study: 26137575
Drug: Single-dose R-bambuterol
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose R-bambuterol (2.5 mg, 5 mg, or 10 mg)
Study: 26137575
Drug: Multiple-dose R-bambuterol
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose R-bambuterol (5 mg)
Study: 26137575
Drug: Single-dose rac-bambuterol
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rac-bambuterol (10 mg)
Study: 24277856
Drug: Intranasal OXT
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal OXT treatment (24 IU)
Study: 22019033
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (behavioral modification only)
Study: 16767844
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg/day) and E (100 mg/day) supplementation
Study: 14709123
Drug: Hydrocortisone infusion
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone infusion (1000 mg in 300 mL normal saline)
Study: 14709123
Drug: Hydrocortisone infusion
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone infusion (1000 mg in 300 mL normal saline) + Chlorpheniramine bolus (10 mg IV)
Study: 8161320
Drug: Pyridostigmine Bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine Bromide (PB) 90 mg per day
Study: 3283384
Drug: Ibuprofen (prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (prophylactic course, dosage not specified)
Study: 31983605
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no alpha-blocker treatment)
Study: 25720546
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate vaginal suppository 1,200 mg
Study: 23259453
Drug: Adefovir 10
Normalized name: adefovir 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 10 mg daily for 48 weeks
Study: 16611389
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (1 g ascorbic acid 2 hours pre- and for 14 days post-exercise)
Study: 10913806
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a beneficial effect on the nonfatal outcome
Study: 10913806
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment effect on mortality)
Study: 8853764
Drug: Ondansetron (5-HT3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (5-HT3 antagonist)
Study: 17461928
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg day(‐1))
Study: 27169919
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg/day)
Study: 25039997
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (Control)
Study: 22230154
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous isotonic saline hydration (control group, n = 83)
Study: 20819439
Drug: Gentamicin-absorbed collagen
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-absorbed collagen sponges placed on the sacral fascia, no oral post-operative antibiotics.
Study: 20819439
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics for 7 days post-operatively (Control group).
Study: 18487550
Drug: Crossover therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover therapy
Study: 14506488
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g CLA per day
Study: 14506488
Drug: 3.6 g
Normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g CLA per day
Study: 8836932
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (L-DOPA/benserazide + bromocriptine, nearly 40% replacement)
Study: 8836932
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (L-DOPA/benserazide + bromocriptine)
Study: 8836932
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (L-DOPA/benserazide + bromocriptine) with > 50% substitution
Study: 1998929
Drug: Geriatric day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric day hospital treatment
Study: 31147367
Drug: Hyperuricaemia (HUA)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperuricaemia (HUA) defined as serum uric acid level >420 μmol/L in men and >360 μmol/L in women
Study: 29274162
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) by Diode Laser GaAlAs (780nm), twice a week for six weeks
Study: 29274162
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (LLLT and lidocaine infiltration)
Study: 27403531
Drug: Acupuncture catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture catgut embedding therapy (ACET) with moxibustion
Study: 11874215
Drug: Clinician-guided behavior
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-guided behavior therapy
Study: 11874215
Drug: Computer-guided behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-guided behavior therapy
Study: 2140743
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg b.i.d.)
Study: 2140743
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ketanserin and captopril (20 mg b.i.d. and 25 mg b.i.d. respectively) for 45 days
Study: 6213682
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin (1% solution)
Study: 6213682
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline (250 mg)
Study: 16495752
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg to 100 mg daily for 6 months
Study: 16495752
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg to 100 mg daily for 6 months
Study: 1355595
Drug: Electrophysiologically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysiologically guided drug therapy
Study: 1355595
Drug: Metoprolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol therapy (for noninducible arrhythmia)
Study: 1355595
Drug: Electrophysiologically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysiologically guided drug therapy (for inducible arrhythmia that became noninducible)
Study: 1355595
Drug: Metoprolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol therapy (for inducible arrhythmia that remained inducible)
Study: 6517245
Drug: Ultra-low-dose droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultra-low-dose droperidol (0.25 mg)
Study: 6517245
Drug: Low-dose droperidol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose droperidol (1.25 mg)
Study: 29329763
Drug: Varenicline (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (titrated to two 0.5 mg doses twice daily)
Study: 19025523
Drug: High-volume (170
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume (170 ml) ropivacaine (0.2%) with epinephrine
Study: 15707562
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses combined
Study: 14616168
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg (R10) + amoxicillin 1,000 mg + clarithromycin 500 mg (AC)
Study: 14616168
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg (R20) + amoxicillin 1,000 mg + clarithromycin 500 mg (AC)
Study: 14616168
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (O) + amoxicillin 1,000 mg + clarithromycin 500 mg (AC)
Study: 10440416
Drug: Clopidogrel 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 25 mg once daily
Study: 10440416
Drug: Clopidogrel 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 100 mg once daily
Study: 10440416
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg once daily
Study: 10440416
Drug: Clopidogrel (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (up to 75 mg)
Study: 1796819
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (Dermovate and another corticosteroid of differing potency) applied for 4 weeks
Study: 1796819
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (another corticosteroid of differing potency) applied for 4 weeks
Study: 6689490
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg daily for 7 days)
Study: 6689490
Drug: Antacid (Maalox,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (Maalox, 105 ml daily for 7 days)
Study: 6689490
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg daily for 7 days) in healthy volunteers
Study: 31342624
Drug: Abatacept 125
Normalized name: abatacept 125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept 125 mg
Study: 23784898
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (5 g/day)
Study: 23784898
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (10 g/day)
Study: 23784898
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant GH (0 μg/kg/day)
Study: 23784898
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant GH (3 μg/kg/day)
Study: 23784898
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant GH (5 μg/kg/day)
Study: 9496213
Drug: Soda lime
Normalized name: SODA LIME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soda lime with 60 ml of water added (water group)
Study: 8201800
Drug: Zopiclone (ZPC)
DrugBank: Zopiclone (DB01198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zopiclone (ZPC) 10 mg
Study: 23907087
Drug: Rectal stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal stimulation and/or small volume enemas
Study: 23907087
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (rectal stimulation/enemas)
Study: 19118966
Drug: Mesalazine in
Normalized name: Product containing mesalazine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine in medication stratum
Study: 17562631
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality distraction intervention during chemotherapy
Study: 17562631
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention (control) during matched chemotherapy treatment
Study: 26628206
Drug: Clinical Case
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical Case Management integrated with Problem-Solving Therapy (CM-PST)
Study: 12690054
Drug: L-dopa treatment
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa treatment
Study: 12690054
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (L-dopa + STN stimulation)